Orbital myositis (OM) is relatively rare but is the next most common cause of extraocular muscle (EOM) disease after thyroid-associated orbitopathy (TAO).1,2 It typically presents as idiopathic acute onset, painful diplopia in young adult females, with inflammation of a single EOM, and usually responds to a course of oral corticosteroids. However, there are many atypical cases. These include chronic and recurrent idiopathic OM, those not responding to corticosteroids, and cases occurring in the setting of systemic inflammatory, autoimmune, and infective conditions, and in response to drugs.
Thyroid-associated orbitopathy is by far the commonest cause of inflammation of EOM, but this review specifically does not address TAO, and summarizes the current state of knowledge of all other forms of OM.
NOMENCLATURE AND CLASSIFICATION
There is no agreed nomenclature or classification system to describe OM. Some case reports and reviews use the term “ocular myositis.”3 Schoser4 suggested using the terms “limited oligosymptomatic ocular myositis” and “severe exophthalmic ocular myositis” to differentiate typical from atypical OM. However, many cases do not fit this simple classification. There is also no agreement on how to describe OM that occurs in the setting of specific inflammatory or autoimmune conditions.
Orbital myositis bears many similarities to uveitis. It is an inflammatory condition, often idiopathic, but also often occurring in the setting of specific autoimmune, inflammatory, and infective conditions. There have been efforts to standardize nomenclature in uveitis.5 This common language assists researchers to define conditions and their response to treatment, and in reporting and comparing their research.6
Using the Standardized Uveitis Nomenclature, and evaluating patients with a thorough history, ophthalmic examination, and targeted investigations, led one tertiary uveitis center to reclassify 52/179 (29.0%) patients with idiopathic uveitis and give them a specific diagnosis.7 Orbital myositis would benefit from a similar systematized approach. After presenting a review of all forms of OM, the author proposes a classification system that might serve as a basis for a clearer understanding of OM and also serve as a framework for future research.
IDIOPATHIC ACUTE OM
Idiopathic acute OM is an uncommon disease but the commonest form of OM. There is acute onset orbital pain, exacerbated by eye movement, with diplopia, often some eyelid swelling, ptosis, and conjunctival chemosis.8 There may be injection over the insertion of the affected muscle. The muscle may be paretic, restricted, or both. On imaging (CT or MRI), there is usually enhancing fusiform enlargement of the muscle belly, often with involvement of the muscle tendon.
Females are more affected, in a ratio of 2:1.8,9 While any age can be affected (range 3–84 years in one meta-analysis), the majority are young adults (mean, 37 years; median, 34).8
Most have a single affected muscle (68% of 75 cases in the series by Siatkowski et al9), with 2 affected muscles in 22%, 3 or more in 10%, and only 1 with bilateral involvement. The relative frequency of involvement of each EOM is listed in Table 1 and differs from that observed in TAO.
Ocular motility varies between patients and over the course of the disease. A few may have normal motility but with pain in the direction of action of the muscle. Siatkowski et al9 noted normal motility for several days, followed by a paretic phase (average, 13 days), then a combined paretic and restrictive phase (mean, 22 days), and finally a restrictive phase lasting 19 days on average. Not all follow this pattern, and many pass straight from a paretic phase to normal function with treatment. Early treatment may prevent later fibrosis and restrictive strabismus. Others have observed differing patterns of motility disturbance at presentation, with pure paresis (20.5%), mixed paretic and restrictive (34.1%), and pure restrictive patterns (45.5%) seen in a large cohort of 44 Chinese patients.10 An extended period of restrictive movement suggests fibrosis in the muscle, and recovery may be incomplete.
Oblique Muscle Myositis.
Orbital myositis of the oblique muscles is relatively uncommon. There are reports of isolated superior11–13 or inferior oblique myositis,14 or both together.15 When the inferior oblique is affected, there is usually marked inferior conjunctival chemosis.16
Levator Palpebrae Superioris Myositis.
There are several cases of isolated levator palpebrae superioris myositis reported,17–21 with acute onset painful ptosis (paresis), reduced levator muscle function, and sometimes eyelid lag on down gaze (restriction). Four acute adult cases responded well to steroids,17–20 but 3 children had a chronic course with poor response to treatment.21
Typical acute idiopathic OM usually responds (68% of 75 cases reported by Siatkowski et al9) within days or weeks to a course of oral corticosteroids. However, recurrence on weaning treatment, or months or years after the episode, is relatively common. Siatkowski et al9 reported recurrences in 15% of 75 patients within 6 months. Mombaerts and Koornneef22 however found that 9 of her 16 cases (56%) had 1 or more recurrence with a disease-free interval of 4.1 months (range, 0.5–17 months). Six of 26 cases of OM reviewed by Mannor et al23 developed recurrent disease. Clinical features associated with recurrence were male gender, multiple EOM involvement, and lack of response to corticosteroids.
Chronic OM usually occurs in patients with a poor response to corticosteroids, raising concerns about the diagnosis. A biopsy should be obtained to exclude other pathologies. Many patients with a chronic course will have an underlying systemic disease and may require steroid-sparing or biologic agents.24
ORBITAL MYOSITIS ASSOCIATED WITH SYSTEMIC INFLAMMATORY AND AUTOIMMUNE DISEASE
Many single case reports or small series describe an association between systemic inflammatory or autoimmune diseases and OM (Table 2). The commonest are immunoglobulin G4–related ophthalmic disease (IgG4-ROD) and inflammatory bowel disease (IBD). Siatkowski et al9 found 4/75 (5.3%) cases with associated diseases (2 IBD, 1 systemic lupus erythematosus [SLE], and 1 relapsing polychondritis),9 Mombaerts and Koornneef22 reported 3/16 (18.8%) (IBD, psoriasis, and Human Leukocyte Antigen – B27 spondyloarthritis), and Patrinely et al54 reported 3/15 (20%) (IBD 1 case, and sarcoidosis in 2). Weinstein et al28 had 3/12 cases (25%) with associated diseases (IBD, SLE, and rheumatoid arthritis), and Yan and Wu10 reported 6/44 (1 SLE, 2 “lumbar rheumatism,” and 3 a preceding upper respiratory tract infection).
The demographic and clinical features of OM occurring in association with other diseases often differ from that seen in idiopathic acute OM. The data of all cases where there have been 4 or more reported in association with the particular condition are summarized in Table 3. The 4 granulomatosis with polyangiitis (GPA or Wegener granulomatosis) cases had insufficient published data to include in the Table 2.
IgG4-Related Ophthalmic Disease.
IgG4-related disease commonly affects the orbit (IgG4-ROD),120,121 and EOM involvement in IgG4-ROD is relatively common (15–37% of IgG4-ROD).25–27 Multiple muscles are usually involved, and in just over half, bilateral EOM disease is seen. Extraocular muscle disease is always seen with other manifestations of IgG4-ROD, commonly infra-orbital nerve enlargement, paranasal sinus disease, and lacrimal gland disease.122 Despite the EOMs being enlarged, usually in a fusiform pattern, patients almost never have pain with eye movement, and eye movements are relatively normal. One study reporting strabismus in IgG4-ROD with EOM disease found that half the patients had normal movements with orthophoria, and half had small-angle tropias.123
Fibrosis does not appear to occur within EOMs to a sufficient degree to lead to restrictive strabismus. The relative lack of motility disturbance and the presence of other features of IgG4-ROD easily differentiates this condition from most other forms of OM.
Inflammatory Bowel Disease.
In 31 reported cases of OM with IBD (27 with Crohn disease and 4 with ulcerative colitis), the pattern of muscle involvement has differed from that seen with idiopathic acute OM.11,24,28–53 Inflammatory bowel disease–associated OM affected single muscles in only 32.2% (68% in idiopathic acute OM) and occurred bilaterally in 45.2% of cases (1.3% in idiopathic acute OM). Recurrent OM was also common in the IBD group (30%). In 6 cases, symptoms of OM preceded the onset of symptoms of IBD, sometimes by as much as 1 to 2 years.24,30,44,45,53
Several cases with IBD have had EOM biopsies. In 3 cases, a nonspecific infiltration of T-lymphocytes was reported,38,53 with some necrosis in one case53 and suppurative granulomatous inflammation in another.40
Most patients were managed with corticosteroids, but 10/23 (43.5%) required additional immunosuppression: infliximab,24,46,48 adalimumab,45,49 azathioprine,48,53 methotrexate, mycophenolate,53 and cyclophosphamide.42 This suggests that OM in IBD is more severe and more resistant to corticosteroids than idiopathic OM.
When orbital sarcoidosis has primarily affected EOM,54–67 bilateral involvement (69%) of multiple muscles (77%) has been common. In 14/16 with clinical details, 10 (71%) had painless diplopia and/or swelling. Sarcoidosis of other sites was known or found in 8/13 cases, and 5/13 had no evidence of sarcoidosis elsewhere on investigation. In 3 cases, lacrimal gland sarcoidosis was also present, and in 2 cases, disease spread from EOM in adjacent orbital fat.
In 11/13 (84.6%), sarcoidosis was diagnosed on EOM biopsy, and 2 had confirmation from biopsies elsewhere. Where treatment was reported, all responded well to corticosteroids.
Systemic and Discoid Lupus Erythematosus.
Of 10 reported cases of OM occurring in patients with SLE (8)9,10,28,68–72 or discoid lupus erythematosus (2),73,74 clinical details have been reported in 8 (6 SLE, 2 discoid lupus erythematosus). Six of 8 (75%) have been bilateral, and 75% were acute in onset. Half were on treatment for SLE when presenting with OM, and one was known to have discoid lupus erythematosus. One patient’s OM was their first presentation of SLE.71
The association of OM with giant-cell myocarditis is rare but important because giant-cell myocarditis carries a high morbidity and mortality.124 There have been 8 reported cases of OM associated with giant-cell myocarditis75–82 and 1 case of fulminant lymphocytic myocarditis.83 Importantly, 7/9 cases of OM have presented before the onset of cardiac symptoms (range, 1 month to 3 years; median, 2 months). Two presented simultaneously with cardiac symptoms.
All 9 cases have had subacute OM with multiple muscles affected, bilaterally in 8/9 (89%), and in 7/9 (78%), pain has been a feature. Three have developed muscle disease elsewhere (bulbar,75,76 proximal limb,75,76 diaphragm83). Five of 9 cases have had EOM biopsies (2 postmortem) and have shown nonspecific lymphocytic infiltrate in all cases, histiocytic infiltrate in 2, and giant cells in only 1.
Presenting cardiac features included cardiac failure and ventricular tachycardia. Four of 9 patients died of cardiac failure, 3 needed cardiac transplant, and only 2 settled with immunosuppression.
Giant-cell myocarditis is associated with many autoimmune conditions,124 and in the 9 patients with OM and giant-cell myocarditis, 2 had vitiligo,77,78 and 1 rheumatoid arthritis.82
After infection with group-A streptococci, inflammatory syndromes including rheumatic fever, reactive arthritis, and glomerulonephritis may occur. Uveitis uncommonly can occur,125 as may OM, with 9 cases confirmed by elevated antistreptolysin titers or positive throat cultures.84–88 Orbital myositis has also been reported after upper respiratory tract infections and flu-like illnesses without confirmation of infection by streptococci.10,22,28,126–128 Eight of these reports were from published series of OM, with 1/6,127 1/12,28 1/6,128 2/16,22 and 3/4410 patients reported to have had a preceding upper respiratory tract infection or flu-like illness (in total 8/84 [9.5%] with this association).
All cases in the confirmed poststreptococcal group have been single muscle OM, and orbital symptoms occurred between 2 and 6 weeks after the streptococcal infection. One patient also had a migratory arthritis.
The 5 women with rheumatoid arthritis all had established rheumatoid arthritis when their OM developed.18,89–92 Two developed OM while on the tumor necrosis factor inhibitor etanercept.91,92
Eosinophilic GPA (or Churg Strauss Syndrome).
All patients in this group had bilateral OM with multiple muscles affected,93–96 but only one reported mild pain.94
All 5 cases presented with single muscle painful OM,24,97–100 with 1 later becoming multiple and bilateral.24 One patient’s OM was their first presentation of Behçet’s.98 Two patients required infliximab24 or cyclophosphamide for control of OM.
GPA (or Wegener Granulomatosis).
Patients with GPA frequently manifest orbital disease, with inflammatory masses often involving EOM, but rarely EOM disease can occur alone. Ismailova et al101 reported the clinical features of 74 GPA patients with orbital disease, dividing them into 3 patterns: an orbital mass without lacrimal gland involvement (60.8%), lacrimal gland involvement (35.1%), and EOM myositis (only 4.1%). In a case of superior oblique OM in a patient with GPA, the disease subsequently infiltrated the orbit more widely.102
ORBITAL MYOSITIS AND INFECTIVE DISEASES
Orbital myositis has been reported in a variety of infective conditions (Table 4). The commonest of these is herpes zoster ophthalmicus.
Herpes Zoster Ophthalmicus.
Orbital inflammation uncommonly occurs with herpes zoster ophthalmicus, including inflammation of EOMs. Twenty-three cases have been reported of OM in the setting of herpes zoster ophthalmicus,15,129–141 16 in females (69.6%), with an age range of 13 to 84 years (mean, 61.8; median, 66 years). Eight of 23 (34.8%) have had clinical and imaging features of OM from 1 to 9 days (most 2–3 days) prior to the development of the vesicular rash. More commonly, the OM has presented a few days after the rash, but 2 cases have developed OM a month later.
On MRI, inflammation of other orbital structures is often seen, including optic nerve sheath, orbital apex tissues, and lacrimal gland. Most cases show swelling in multiple or all EOMs, with only 4/23 (17.4%) having a single affected EOM. Treatment has usually been with a combination of antivirals (acyclovir) and oral steroids.
A case of acute single muscle OM after primary varicella zoster virus infection (chicken pox) has been published.151
In 8 cases of OM in Lyme disease, half have been male, with ages ranging from 5 to 68 years (mean, 39; median, 46).142–148 All were acute onset and unilateral, with half affecting a single muscle, and half 2 or more. Pain was a feature in 5, and 1 had recurrent episodes.
The commonest parasitic infestation affecting EOMs is cysticercosis. It is common in areas of poor sanitation. If the orbit is affected, 80% of cases involve EOM.153 The involved EOM is often grossly enlarged with a cystic area within it seen on CT scan or B-scan ultrasonography. Treatment is with albendazole and corticosteroids.
ORBITAL MYOSITIS AS A DRUG REACTION
Several medications have been associated with OM in various forms (Table 5). The commonest have been relatively new monoclonal antibodies (ipilimumab and other immune checkpoint inhibitors [ICIs], and the anti–cluster of differentiation-52 alemtuzumab) and bisphosphonates.
Ipilimumab and Other ICIs.
Immune checkpoint inhibitors are used to treat systemic malignancies, especially metastatic melanoma, and target 1 of 3 ligands: cytotoxic T-lymphocyte antigen-4 (ipilimumab), programmed (cell) death protein 1 (pembrolizumab, nivolumab), and programmed (cell) death ligand-1 (programmed [cell] death ligand-1, atezolizumab, avelumab, durvalumab). They activate T-cells, which attack malignant cells, but also upregulate the immune system with frequent autoimmune-like side effects, including uveitis, dry eye, myasthenia gravis, and sclerokeratitis.180 The commonest orbital manifestation is a TAO-like reaction, but other patterns of myositis have been described.
Of 17 cases reported,154–164 12 have presented with features similar to acute onset TAO, which has been bilateral in all but 1 case.156 Thyroid function (reported in 6 cases) was normal in 4, overactive in 1, and underactive in 1 patient who also had hypophysitis.162 Abnormal thyroid antibodies were documented in only 2 cases154,155 and were normal in 8. One patient with preexisting-treated Graves disease developed a TAO-like reaction after starting treatment with a programmed (cell) death protein 1 inhibitor.164
The clinical features of the TAO-like presentation have differed from typical TAO. The onset has been acute and has followed infusion of the ICI within 1 or several days, but not always after the first infusion. Inflammation has often been severe with marked conjunctival chemosis and limited eye movements. Usually, most or all the EOMs have been involved. One patient has had optic neuropathy which responded well to medical treatment.158 Many patients have had ptosis rather than eyelid retraction. Response to withholding the drug and giving corticosteroids has often been rapid and complete or near complete.
Three cases have described complete ophthalmoplegia and ptosis in response to ICIs.161–163 In 1 case, the EOMs were not enlarged, and the patient also developed severe cardiac and skeletal myositis which proved fatal.163 Single muscle OM has been described in only 2 patients after receiving ICIs.160,161
Alemtuzumab is an anti-cluster of differentiation-52 monoclonal antibody, which depletes circulating B- and T-lymphocytes and is used most commonly in the treatment of relapsing-remitting multiple sclerosis but also in hematologic disorders. Autoimmune disorders complicate treatment in nearly 50% of patients. Thyroid dysfunction, the commonest, occurred in 34% of patients having alemtuzumab in 1 trial, with 22% developing Graves hyperthyroidism, 7% hypothyroidism, and 4% subacute thyroiditis.165
Fourteen cases of TAO after alemtuzumab have been reported.166–169 The largest series reported one center’s experience with 162 patients treated with alemtuzumab for multiple sclerosis, of whom 71 (44%) developed thyroid dysfunction (62 [87%] of these were Graves disease).169 Ten patients of 62 (16%) developed TAO which ranged from mild to severe sight-threatening disease. All had elevated thyroid stimulating hormone receptor antibodies, and all were managed medically.
Bisphosphonates inhibit bone resorption by reducing osteoclast function and are used in the treatment of osteoporosis, osteolytic bone tumors and metastases, and Paget disease. Orbital inflammation is increasingly recognized as a side effect. Among cases of orbital inflammation, OM has been reported.
Of 11 cases with OM featuring in the presentation, 6 have been female.170–175 Bilateral OM has occurred in 6 cases, and only 3 have had isolated single muscle OM without features of inflammation beyond EOM.175 All other cases have had multiple muscles affected, with painful eye movements and diplopia in most. Acute onset of symptoms occurs within 0 to 28 days of exposure to the drug. Zoledronate has been the commonest inciting cause, being responsible for 22 of 29 cases of orbital inflammation summarized by Pirbhai et al.174
Treatment has been with corticosteroids, intravenously and/or orally, and response has usually been rapid and complete.
Statins (3-hydroxy-3-methylglutaryl-co-enzyme A reductase inhibitors) are very widely prescribed drugs used to reduce cholesterol levels. Generalized skeletal myopathy occurs in 1% to 5% of patients in clinical trials and 10% to 15% in observational studies.176 There is a single case report of OM with supportive orbital imaging in a 45-year-old man on simvastatin.176 The OM settled on withdrawal of the drug and recurred with rechallenge. This same article reported documented adverse drug reactions to statins of diplopia in 361 cases, proptosis in 8, and ophthalmoplegia in 83, suggesting that OM is much commoner than the lack of publications would suggest.
In 2008, Fraunfelder and Richards177 published a article documenting 256 cases of ptosis, diplopia, and ophthalmoplegia in patients taking satins, many of whom had dechallenge and rechallenge to confirm the relationship between drug and adverse effect. Orbital imaging was not reported. They surmised that the most plausible mechanism of action was myositis of the EOMs and levator muscles.
PARANEOPLASTIC ORBITAL MYOSITIS
Enlargement of EOMs presumably due to inflammation has been described as a paraneoplastic phenomenon in a small number of cases (Table 6).181–188 In all cases, the OM has been bilateral and affected most or all EOMs. One case in a patient with breast cancer had bilateral superior rectus involvement only.181
In the most cases, the OM resolved or improved significantly, and quite rapidly, with removal of the primary lesion, sometimes with the addition of oral corticosteroids. In the case of OM in association with high-grade non-Hodgkin lymphoma, there were associated neurologic abnormalities, and these and the OM improved with immunosuppression.187 This patient had an EOM biopsy showing destruction of myofibers and granulomatous inflammation.
Orbital myositis shares many features with uveitis. Extraocular muscle is a target for an inflammatory response in many autoimmune, inflammatory, and infective conditions, but a large proportion remains “idiopathic.” In the past, there has been no attempt to classify OM in a systematic way. Based on the above review of all forms of OM, the author would propose a relatively simple but comprehensive classification, which is detailed in Table 7. This could serve as the basis for future reports, discussions, and research, with a potentially agreed common language to describe the various forms of OM.
A careful and systematic approach to any patient presenting with features of OM will more likely identify an underlying or associated disease or cause and reduce the proportion labeled as idiopathic. A full medical history to detect possible associated or underlying causes of OM and a full drug history are mandatory. Orbital imaging should be obtained, and a contrast-enhanced MRI is more useful than CT. Involvement of other structures such as lacrimal gland (TAO, sarcoidosis, GPA, IgG4-ROD), orbital nerves (IgG4-ROD), and paranasal sinuses (IgG4-ROD, GPA) should be looked for.
Targeted investigations aimed at possible underlying or associated inflammatory or autoimmune conditions should be performed. If a patient has atypical features, then strong consideration should be given to obtaining a biopsy of affected EOM.
Patients should be warned of possible future recurrent disease or the development of associated systemic medical conditions.
With this approach, OM will likely be less often an idiopathic disease.
1. Lacey B, Chang W, Rootman J. Nonthyroid causes of extraocular muscle disease. Surv Ophthalmol 1999;44:187–213.
2. Eade EL, Hardy TG, McKelvie PA, et al. Review of extraocular muscle biopsies and utility of biopsy in extraocular muscle enlargement. Br J Ophthalmol 2018;102:1586–90.
3. Fraser CL, Skalicky SE, Gurbaxani A, et al. Ocular myositis. Curr Allergy Asthma Rep 2013;13:315–21.
4. Schoser BG. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review. Clin Ophthalmol 2007;1:37–42.
5. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–16.
6. Trusko B, Thorne J, Jabs D, et al; Standardization of Uveitis Nomenclature (SUN) Project. The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 2013;52:259–65, S1–6.
7. Choi RY, Rivera-Grana E, Rosenbaum JT. Reclassifying idiopathic uveitis: lessons from a tertiary uveitis center. Am J Ophthalmol 2019;198:193–9.
8. Scott IU, Siatkowski RM. Idiopathic orbital myositis. Curr Opin Rheumatol 1997;9:504–12.
9. Siatkowski RM, Capó H, Byrne SF, et al. Clinical and echographic findings in idiopathic orbital myositis. Am J Ophthalmol 1994;118:343–50.
10. Yan J, Wu P. Idiopathic orbital myositis. J Craniofac Surg 2014;25:884–7.
11. Moorman CM, Elston JS. Acute orbital myositis. Eye (Lond) 1995;9 (pt 1):96–101.
12. Stidham DB, Sondhi N, Plager D, et al. Presumed isolated inflammation of the superior oblique muscle in idiopathic orbital myositis. Ophthalmology 1998;105:2216–9.
13. Kau HC, Kao SC, Peng CH, et al. Methylprednisolone pulse therapy in patient with isolated superior oblique myositis. Eye (Lond) 2006;20:1106–9.
14. Lahoud S, Brownstein S, Barsoum-Homsy M. Inferior oblique myositis presenting as superior oblique muscle palsy. Can J Ophthalmol 1988;23:124–7.
15. Badilla J, Dolman PJ. Orbital myositis involving the oblique muscles associated with herpes zoster ophthalmicus. Ophthalmic Plast Reconstr Surg 2007;23:411–3.
16. Wan WL, Cano MR, Green RL. Orbital myositis involving the oblique muscles. An echographic study. Ophthalmology 1988;95:1522–8.
17. Rice CD, Gray LD. Isolated levator myositis. Ophthalmic Plast Reconstr Surg 1988;4:167–70.
18. Wheatcroft S, Elston J. Unilateral ptosis due to isolated involvement of the levator muscle in acute orbital myositis. Br J Ophthalmol 1999;83:631–2.
19. Almekhlafi MA, Fletcher WA. Levator palpebrae myositis. Neurology 2008;71:1202.
20. Court JH, Janicek D. Acute unilateral isolated ptosis. BMJ Case Rep 2015;2015. doi: 10.1136/bcr-2014–207720.
21. Rasiah S, Hardy TG, Elder JE, et al. Etiology of pediatric acquired blepharoptosis. J AAPOS 2017;21:485–7.
22. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology 1997;104:402–8.
23. Mannor GE, Rose GE, Moseley IF, et al. Outcome of orbital myositis. Clinical features associated with recurrence. Ophthalmology 1997;104:409–13; discussion, 414.
24. Garrity JA, Coleman AW, Matteson EL, et al. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004;138:925–30.
25. Sogabe Y, Ohshima K, Azumi A, et al. Location and frequency of lesions in patients with IgG4-related ophthalmic diseases. Graefes Arch Clin Exp Ophthalmol 2014;252:531–8.
26. Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum 2014;43:806–17.
27. Ebbo M, Patient M, Grados A, et al. Ophthalmic manifestations in IgG4-related disease: clinical presentation and response to treatment in a French case-series. Medicine (Baltimore) 2017;96:e6205.
28. Weinstein GS, Dresner SC, Slamovits TL, et al. Acute and subacute orbital myositis. Am J Ophthalmol 1983;96:209–17.
29. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401–12.
30. Young RS, Hodes BL, Cruse RP, et al. Orbital pseudotumor and Crohn disease. J Pediatr 1981;99:250–2.
31. Camfield PR, White M, Warner HA, et al. Orbital pseudotumor and Crohn disease. J Pediatr 1982;101:157–8.
32. Verbraeken H, Ryckaert S, Demets W. Pseudotumor of the orbit and Crohn’s disease. Bull Soc Belge Ophtalmol 1984;210:65–72.
33. Weinstein JM, Koch K, Lane S. Orbital pseudotumor in Crohn’s colitis. Ann Ophthalmol 1984;16:275–8.
34. Squires RH Jr, Zwiener RJ, Kennedy RH. Orbital myositis and Crohn’s disease. J Pediatr Gastroenterol Nutr 1992;15:448–51.
35. Smith JW. Orbital pseudotumor and Crohn’s disease. Am J Gastroenterol 1992;87:405–6.
36. Durno CA, Ehrlich R, Taylor R, et al. Keeping an eye on Crohn’s disease: orbital myositis as the presenting symptom. Can J Gastroenterol 1997;11:497–500.
37. Jain S, Gottlob I. Orbital myositis associated with ulcerative colitis. Am J Gastroenterol 2001;96:3442–4.
38. Maalouf T, Angioï K, George JL. Recurrent orbital myositis and Crohn’s disease. Orbit 2001;20:75–80.
39. Macarez R, Bazin S, Weber F, et al. [Orbital myositis associated with ulcerative colitis]. J Fr Ophtalmol 2005;28:610–3.
40. Leibovitch I, Galanopoulos A, Selva D. Suppurative granulomatous myositis of an extra-ocular muscle in Crohn’s disease. Am J Gastroenterol 2005;100:2136–7.
41. Ramalho J, Castillo M. Imaging of orbital myositis in Crohn’s disease. Clin Imaging 2008;32:227–9.
42. Culver EL, Salmon JF, Frith P, et al. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn’s disease: case report and systematic literature review. J Crohns Colitis 2008;2:337–42.
43. Cheng S, Vu P. Recurrent orbital myositis with radiological feature mimicking thyroid eye disease in a patient with Crohn’s disease. Orbit 2009;28:368–70.
44. Bourikas LA, Roussomoustakaki M, Papadaki E, et al. A case of orbital myositis preceding the intestinal symptoms of Crohn’s disease. J Crohns Colitis 2010;4:349–50.
45. Hernández-Garfella ML, Gracia-García A, Cervera-Taulet E, et al. Adalimumab for recurrent orbital myositis in Crohn’s disease: report of a case with a 3-year follow-up. J Crohns Colitis 2011;5:265–6.
46. Bennion J, Harris MA, Sivak-Callcott JA, et al. Bilateral diffuse orbital myositis in a patient with relapsing ulcerative colitis. Ophthalmic Plast Reconstr Surg 2012;28:e119–20.
47. Kondolot M, Unal E, Poyrazoglu G, et al. Orbital myositis associated with focal active colitis in a teenage girl. Childs Nerv Syst 2012;28:641–3.
48. Pimentel R, Lago P, Pedroto I. Recurrent orbital myositis as an extra-intestinal manifestation of Crohn’s disease. J Crohns Colitis 2012;6:958–9.
49. Verma S, Kroeker KI, Fedorak RN. Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature. BMC Gastroenterol 2013;13:59.
50. Zenone T. Orbital myositis and Crohn’s disease. Int J Rheum Dis 2014;17:481–2.
51. Biotti D, Toulemonde P, Brassat D, et al. Teaching neuroimages: painful diplopia and Crohn disease. Neurology 2016;16:e68–9.
52. Önder Ö, Bilgin RR, Köşkderelioğlu A, et al. Orbital myositis: evaluating five new cases regarding clinical and radiological features. Noro Psikiyatr Ars 2016;53:173–7.
53. Vargason CW, Mawn LA. Orbital myositis as both a presenting and associated extraintestinal sign of Crohn’s disease. Ophthalmic Plast Reconstr Surg 2017;33(3S suppl 1):158–60.
54. Patrinely JR, Osborn AG, Anderson RL, et al. Computed tomographic features of nonthyroid extraocular muscle enlargement. Ophthalmology 1989;96:1038–47.
55. Stannard K, Spalton DJ. Sarcoidosis with infiltration of the external ocular muscles. Br J Ophthalmol 1985;69:562–6.
56. Cornblath WT, Elner V, Rolfe M. Extraocular muscle involvement in sarcoidosis. Ophthalmology 1993;100:501–5.
57. Patel AS, Kelman SE, Duncan GW, et al. Painless diplopia caused by extraocular muscle sarcoid. Arch Ophthalmol 1994;112:879–80.
58. Brooks SE, Sangueza OP, Field RS. Extraocular muscle involvement in sarcoidosis: a clinicopathologic report. J AAPOS 1997;1:125–8.
59. Simon EM, Zoarski GH, Rothman MI, et al. Systemic sarcoidosis with bilateral orbital involvement: MR findings. AJNR Am J Neuroradiol 1998;19:336–7.
60. Biswas J, Krishnakumar S, Raghavendran R, et al. Lid swelling and diplopia as presenting features of orbital sarcoid. Indian J Ophthalmol 2000;48:231–3.
61. Menon GJ, Hollman AS, Dutton GN. Granulomatous orbital myositis. Eye (Lond) 2000;14 (pt 4):676–8.
62. Takahashi T, Fujita N, Takeda K, et al. [A case of sarcoid myopaty with external ocular muscle involvement–diagnosis and follow-up study with 99mTc pyrophosphate scintigraphy]. Rinsho Shinkeigaku 2000;40:145–8.
63. Hayashi E, Niwa A, Narita Y, et al. [A case of sarcoidosis with simultaneous involvement of the lower brainstem and the whole cervical cord and the extraocular muscles]. Rinsho Shinkeigaku 2001;41:314–7.
64. So WL, Hardy TG, McKelvie P. Atypical clinical presentation of isolated extraocular muscle sarcoid. Case Rep Ophthalmol Med 2012;2012:370258.
65. Hayashi Y, Ishii Y, Nagasawa J, et al. Subacute sarcoid myositis with ocular muscle involvement; a case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis 2016;33:297–301.
66. Kim JS, Scawn RL, Lee BW, et al. Masquerading orbital sarcoidosis with isolated extraocular muscle involvement. Open Ophthalmol J 2016;10:140–5.
67. Sah BP, Sharma B, Iannuzzi MC. Isolated extraocular orbital mass: a rare presentation of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016;33:302–4.
68. Grimson BS, Simons KB. Orbital inflammation, myositis, and systemic lupus erythematosus. Arch Ophthalmol 1983;101:736–8.
69. Serop S, Vianna RN, Claeys M, et al. Orbital myositis secondary to systemic lupus erythematosus. Acta Ophthalmol (Copenh) 1994;72:520–3.
70. Santosa A, Vasoo S. Orbital myositis as manifestation of systemic lupus erythematosus–a case report. Postgrad Med J 2013;89:59.
71. Jenkins PO, Soper C, MacKinnon AD, et al. Systemic lupus erythematosus presenting as orbital myositis. Neuroophthalmology 2014;38:264–7.
72. Rico M, Díaz-López JB, Peña J, et al. Latent orbital pseudotumor secondary to systemic lupus erythematosus. Clin Case Rep 2016;4:1065–7.
73. Arrico L, Abbouda A, Bianchi S, et al. Acute monolateral proptosis and orbital myositis in a patient with discoid lupus erythematosus: a case report. J Med Case Rep 2014;8:375.
74. Kono S, Takashima H, Suzuki D, et al. Orbital myositis associated with discoid lupus erythematosus. Lupus 2014;23:220–2.
75. Klein BR, Hedges TR III, Dayal Y, et al. Orbital myositis and giant cell myocarditis. Neurology 1989;39:988–90.
76. Kattah JC, Zimmerman LE, Kolsky MP, et al. Bilateral orbital involvement in fatal giant cell polymyositis. Ophthalmology 1990;97:520–5.
77. Leib ML, Odel JG, Cooney MJ. Orbital polymyositis and giant cell myocarditis. Ophthalmology 1994;101:950–4.
78. Stevens AW, Grossman ME, Barr ML. Orbital myositis, vitiligo, and giant cell myocarditis. J Am Acad Dermatol 1996;35(2 pt 2):310–2.
79. Kollmeier M, Brodhun M, Sliwka U, et al. [Diplopia and cardiogenic shock]. Nervenarzt 2006;77:187–8, 901.
80. Lind-Ayres MR, Abramowsky C, Mahle WT. Pediatric giant cell myocarditis and orbital myositis. Pediatr Cardiol 2009;30:510–2.
81. Ali MS, Mba BI, Husain AN, Cifci FD. Giant cell myocarditis: a life threatening disorder heralded by orbital myositis. BMJ Case Rep 2016;2016. doi: 10.1136/bcr-2015–213759.
82. Garg V, Tan W, Ardehali R, et al. Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation. ESC Heart Fail 2017;4:371–5.
83. Kwon OH, Kim MN, Kim SA, et al. Fulminant lymphocytic myocarditis associated with orbital myositis and diaphragmatic paralysis. Cardiovasc Pathol 2016;25:55–8.
84. Purcell JJ Jr, Taulbee WA. Orbital myositis after upper respiratory tract infection. Arch Ophthalmol 1981;99:437–8.
85. Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. Optometry 2005;76:250–8.
86. Alshaikh M, Kakakios AM, Kemp AS. Orbital myositis following streptococcal pharyngitis. J Paediatr Child Health 2008;44:233–4.
87. Belanger C, Zhang KS, Reddy AK, et al. Inflammatory disorders of the orbit in childhood: a case series. Am J Ophthalmol 2010;150:460–3.
88. Rabina G, Leibovitch I, Abumanhal M, et al. Orbital inflammatory syndrome post Group A streptococcal infection - case series and review of literature. Ocular Immunol Inflamm 2019;27:162–167. doi: 10.1080/09273948.2017.1367408.
89. Panfilio CB, Hernández-Cossio O, Hernández-Fustes OJ. Orbital myositis and rheumatoid arthritis: case report. Arq Neuropsiquiatr 2000;58:174–7.
90. Nabili S, McCarey DW, Browne B, et al. A case of orbital myositis associated with rheumatoid arthritis. Ann Rheum Dis 2002;61:938–9.
91. Caramaschi P, Biasi D, Carletto A, et al. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol 2003;21:136–7.
92. Couderc M, Mathieu S, Tournadre A, et al. Acute ocular myositis occurring under etanercept for rheumatoid arthritis. Joint Bone Spine 2014;81:445–6.
93. Takanashi T, Uchida S, Arita M, et al. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome: report of two cases and review of the literature. Ophthalmology 2001;108:1129–33.
94. Billing K, Malhotra R, Selva D, et al. Orbital myositis in Churg-Strauss syndrome. Arch Ophthalmol 2004;122:393–6.
95. Fujii T, Norizuki M, Kobayashi T, et al. A case of eosinophilic orbital myositis associated with CSS. Mod Rheumatol 2010;20:196–9.
96. Pradeep TG, Prabhakaran VC, McNab A, et al. Diffuse bilateral orbital inflammation in Churg- Strauss syndrome. Ophthalmic Plast Reconstr Surg 2010;26:57–9.
97. Roh JH, Koh SB, Kim JH. Orbital myositis in Behçet’s disease: a case report with MRI findings. Eur Neurol 2006;56:44–5.
98. Bouomrani S, Farah A, Bouassida N, et al. [Orbital inflammatory pseudotumor with optic neuritis in Behçet’s disease]. J Fr Ophtalmol 2012;35:439.e1–6.
99. Chebbi W, Jerbi S, Ammari W, et al. Orbital myositis in Behçet’s disease. Joint Bone Spine 2014;81:264.
100. Dursun D, Akova Y, Yücel E. Myositis and scleritis associated with Behcet’s disease: an atypical presentation. Ocul Immunol Inflamm 2004;12:329–32.
101. Ismailova DS, Abramova JV, Novikov PI, et al. Clinical features of different orbital manifestations of granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol 2018;256:1751–6.
102. Salam A, Meligonis G, Malhotra R. Superior oblique myositis as an early feature of orbital Wegener’s granulomatosis. Orbit 2008;27:203–6.
103. Thorne JE, Volpe NJ, Liu GT. Magnetic resonance imaging of acquired Brown syndrome in a patient with psoriasis. Am J Ophthalmol 1999;127:233–5.
104. Ajitsaria R, Dale R, Ferguson V, et al. Psoriasis, psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol 2001;26:274–5.
105. Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol 2012;47:e42–3.
106. Danlos FX, Daoued F, Seror R, et al. Orbital myositis and primary Sjögren syndrome. J Rheumatol 2015;42:1536–7.
107. Moon JS, Shin SY. Superior oblique myositis causing acquired Brown’s syndrome as the first manifestation of primary Sjögren’s syndrome. Clin Exp Rheumatol 2018;36 (suppl 112):237–8.
108. Kokotis P, Theodossiadis P, Bouros C, et al. Bilateral ocular myositis as a late complication of dermatomyositis. J Rheumatol 2005;32:379–81.
109. Younes M, Béjia I, Moussa A, et al. [Oculomotor muscles involvement revealing dermatomyositis in a patient with rheumatoid arthritis]. Rev Med Interne 2004;25:829–32.
110. Sachdeva A, Kramer N, Rosenstein ED. Orbital inflammatory disease: unusual presentation of enthesitis in an HLA-B27 spondyloarthropathy. Ocular Immunol Inflamm 2012;20:468–70.
111. Arnett FC, Michels RG. Inflammatory ocular myopathy in systemic sclerosis (scleroderma). A case report and review of the literature. Arch Intern Med 1973;132:740–3.
112. Roulez FM, Dangoisse C, Dufour D, et al. Orbital myositis in a child with linear scleroderma en coup de sabre. J Pediatr Ophthalmol Strabismus 2007;44:264–6.
113. Kim DH, Kim HS. Recurrent orbital myositis in undifferentiated connective tissue disease. Joint Bone Spine 2013;80:110–1.
114. Cerman E, Esen F, Eraslan M, et al. Orbital myositis associated with celiac disease. Int Ophthalmol 2014;34:635–8.
115. Magrini L, Rotiroti G, Conti F, et al. Orbital myositis in a patient with primary biliary cirrhosis: successful treatment with methotrexate and corticosteroids. Isr Med Assoc J 2003;5:825–6.
116. Lin H, Burton EM, Felz MW. Orbital myositis due to Kawasaki’s disease. Pediatr Radiol 1999;29:634–6.
117. Takeuchi A, Taguchi M, Satoh Y, et al. Bilateral orbital inflammation following intravesical bacille Calmette-Guérin immunotherapy for bladder cancer. Jpn J Ophthalmol 2012;56:187–9.
118. Na S, Kim T. Orbital myositis as a manifestation of primary antiphospholipid syndrome. Neurol Sci 2018;39:785–7.
119. Yao Q, Ruggieri P, Lowder C. Ocular myositis occurring with NOD2-associated autoinflammatory disease. J Rheumatol 2013;40:1768–9.
120. McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part I: background and pathology. Ophthalmic Plast Reconstr Surg 2015;31:83–8.
121. McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part II: clinical aspects. Ophthalmic Plast Reconstr Surg 2015;31:167–78.
122. Hardy TG, McNab AA, Rose GE. Enlargement of the infraorbital nerve: an important sign associated with orbital reactive lymphoid hyperplasia or immunoglobulin g4-related disease. Ophthalmology 2014;121:1297–303.
123. Kim N, Yang HK, Kim JH, et al. IgG4-related ophthalmic disease involving extraocular muscles: case series. BMC Ophthalmol 2018;18:162.
124. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336:1860–6.
125. Curragh DS, McAvoy CE, Rooney M, et al. Post-streptococcal uveitis syndrome in a Caucasian population: a case series. Eye (Lond) 2019;33:380–4.
126. Casteels I, De Bleecker C, Demaerel P, et al. Orbital myositis following an upper respiratory tract infection: contribution of high resolution CT and MRI. J Belge Radiol 1991;74:45–7.
127. Slavin ML, Glaser JS. Idiopathic orbital myositis: report of six cases. Arch Ophthalmol 1982;100:1261–5.
128. Hankey GJ, Silbert PL, Edis RH, et al. Orbital myositis: a study of six cases. Aust N Z J Med 1987;17:585–91.
129. Volpe NJ, Shore JW. Orbital myositis associated with herpes zoster. Arch Ophthalmol 1991;109:471–2.
130. Kawasaki A, Borruat FX. An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol 2003;136:574–5.
131. Krasnianski M, Sievert M, Bau V, et al. External ophthalmoplegia due to ocular myositis in a patient with ophthalmic herpes zoster. Neuromuscul Disord 2004;14:438–41.
132. Tseng YH. Acute orbital myositis heralding herpes zoster ophthalmicus: report of a case. Acta Neurol Taiwan 2008;17:47–9.
133. Kim HT, Moon SY, Lee KH. Acute orbital myositis before herpes zoster ophthalmicus. Korean J Anesthesiol 2012;62:295–6.
134. Paraskevas GP, Anagnostou E, Vassilopoulou, Spengos K. Painful ophthalmoplegia with simultaneous orbital myositis, optic and oculomotor nerve inflammation and trigeminal nucleus involvement in a patient with herpes zoster ophthalmicus. BMJ Case Rep 2012;2012. doi: 10.1136/bcr-2012–007063.
135. Patheja RS, Weaver T, Morris S. Unique case of orbital myositis and dacryoadenitis preceding the vesicular rash of herpes zoster ophthalmicus. Clin Exp Ophthalmol 2016;44:138–40.
136. Temnogorod J, Pointdujour-Lim R, Mancini R, et al. Acute orbital syndrome in herpes zoster ophthalmicus: clinical features of 7 cases. Ophthalmic Plast Reconstr Surg 2017;33:173–7.
137. Conrady CD, Feist RM Jr, Crum A. Shingles as the underlying cause of orbital myositis in an adolescent: a case report. Am J Ophthalmol Case Rep 2017;5:111–3.
138. Loubet A, Vendrell JF, Macri F, et al. Orbital myositis: a rare complication of ophthalmic herpes zoster. Diagn Interv Imaging 2017;98:79–81.
139. Daswani M, Bhosale N, Shah VM. Rare case of herpes zoster ophthalmicus with orbital myositis, oculomotor nerve palsy and anterior uveitis. Indian J Dermatol Venereol Leprol 2017;83:365–7.
140. Bak E, Kim N, Khwarg SI, et al. Case series: herpes zoster ophthalmicus with acute orbital inflammation. Optom Vis Sci 2018;95:405–10.
141. Chiang E, Bajric J, Harris GJ. Herpes zoster ophthalmicus with orbital findings preceding skin rash. Ophthalmic Plast Reconstr Surg 2018;34:e113–5.
142. Seidenberg KB, Leib ML. Orbital myositis with Lyme disease. Am J Ophthalmol 1990;109:13–6.
143. Fatterpekar GM, Gottesman RI, Sacher M, et al. Orbital Lyme disease: MR imaging before and after treatment: case report. AJNR Am J Neuroradiol 2002;23:657–9.
144. Carvounis PE, Mehta AP, Geist CE. Orbital myositis associated with Borrelia burgdorferi
(Lyme disease) infection. Ophthalmology 2004;111:1023–8.
145. Holak H, Holak N, Huzarska M, et al. Tick inoculation in an eyelid region: report on five cases with one complication of the orbital myositis associated with Lyme borreliosis. Klin Oczna 2006;108:220–4.
146. Pendse S, Bilyk JR, Lee MS. The ticking time bomb. Surv Ophthalmol 2006;51:274–9.
147. Nieto JC, Kim N, Lucarelli MJ. Dacryoadenitis and orbital myositis associated with Lyme disease. Arch Ophthalmol 2008;126:1165–6.
148. Sauer A, Speeg-Schatz C, Hansmann Y. Two cases of orbital myositis as a rare feature of Lyme borreliosis. Case Rep Infect Dis 2011;2011:372470.
149. Orssaud C, Poisson M, Gardeur D. [Orbital myositis, recurrence of Whipple’s disease]. J Fr Ophtalmol 1992;15:205–8.
150. Huerva V, Espinet R, Galindo C. Recurrent orbital inflammation and Whipple disease. Ocul Immunol Inflamm 2008;16:37–9.
151. Kim JH, Lee SJ, Kim M. External ophthalmoplegia with orbital myositis in an adult patient after chickenpox infection. BMJ Case Rep 2014;2014. doi: 10.1136/bcr-2013–202415.
152. Gil P, Gil J, Paiva C, et al. Medical and surgical treatment in pediatric orbital myositis associated with Coxsackie
Virus. Case Rep Ophthalmol Med 2015;2015:917275.
153. Rath S, Honavar SG, Naik M, et al. Orbital cysticercosis: clinical manifestations, diagnosis, management, and outcome. Ophthalmology 2010;117:600–5, 605.e1.
154. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011;164:303–7.
155. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 2011;27:e87–8.
156. Lecouflet M, Verschoore M, Giard C, et al. [Orbital myositis associated with ipilimumab]. Ann Dermatol Venereol 2013;140:448–51.
157. McElnea E, Ní Mhéalóid A, Moran S, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014;33:424–7.
158. Sohrab MA, Desai RU, Chambers CB, et al. Re: “Drug-induced Graves disease from CTLA-4 receptor suppression”. Ophthalmic Plast Reconstr Surg 2013;29:239–40.
159. Henderson AD, Thomas DA. A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthalmic Plast Reconstr Surg 2015;31:e68–70.
160. Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm 2016;24:140–6.
161. Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, et al. Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother 2017;40:282–5.
162. Sheldon CA, Kharlip J, Tamhankar MA. Inflammatory orbitopathy associated with ipilimumab. Ophthalmic Plast Reconstr Surg 2017;33(3S suppl 1):155–8.
163. Alnabulsi R, Hussain A, DeAngelis D. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit 2018;37:381–4.
164. Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg 2019;35:50–2.
165. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80–9.
166. Tsourdi E, Gruber M, Rauner M, et al. Graves’ disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens) 2015;14:148–53.
167. Trinh T, Haridas AS, Sullivan TJ. Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthalmic Plast Reconstr Surg 2016;32:e128–9.
168. Cima LN, Lambrescu IM, Stejereanu L, et al. Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy? Clin Case Rep 2018;6:867–70.
169. Roos JCP, Moran C, Chatterjee VK, et al. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series. Eye (Lond) 2019;33:223–9.
170. Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford) 2001;40:956–7.
171. Phillips PM, Newman SA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol 2008;126:137–9.
172. Yang EB, Birkholz ES, Lee AG. Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol 2010;30:94–5.
173. Vora MM, Rodgers IR, Uretsky S. Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells–a report and review of 2 cases. Ophthalmic Plast Reconstr Surg 2014;30:e84–5.
174. Pirbhai A, Rajak SN, Goold LA, et al. Bisphosphonate-induced orbital inflammation: a case series and review. Orbit 2015;34:331–5.
175. Lefebvre DR, Mandeville JT, Yonekawa Y, et al. A case series and review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm 2016;24:134–9.
176. Bahrami B, Rajak S, Selva D. Orbital myositis secondary to statin therapy. Med J Aust 2015;203:365.
177. Fraunfelder FW, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 2008;115:2282–5.
178. Rajak S, Sullivan T, Selva D. Orbital myositis: a side effect of interferon alpha 2b treatment. Ophthalmic Plast Reconstr Surg 2015;31:75.
179. Thurairajan G, Hope-Ross MW, Situnayake RD, et al. Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 1997;36:120–3.
180. Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 2018;38:1063–78.
181. Mehta P, Chickadasarahally S, Hedley N, et al. Extraocular muscle enlargement as a paraneoplastic effect of breast carcinoma in a male patient. Ophthalmic Plast Reconstr Surg 2011;27:e146–7.
182. Kiziltunc PB, Atilla H, Akbostanci C, et al. Lacrimal gland metastasis and paraneoplastic orbital myositis due to breast carcinoma. Int J Ophthalmic Pathol 2016;5. doi: 10.4172/2324–8599.1000177.
183. Guiney M, Buckley C, Radford N, et al. A case of seminoma-associated orbitopathy. Aust N Z J Ophthalmol 1995;23:335–7.
184. Taylor JB, Solomon DH, Levine RE, et al. Exophthalmos in seminoma. Regression with steroids and orcheictomy. JAMA 1978;240:860–2.
185. Diacon AH, Schuurmans MM, Colesky FJ, et al. Paraneoplastic bilateral proptosis in a case of non-small cell lung cancer. Chest 2003;123:627–9.
186. Eckel F, Ugi I, Schmidt T, et al. [A 44-year-old patient with cardial carcinoma and paraneoplastic orbital disease]. Dtsch Med Wochenschr 1998;123:1103–6.
187. Harris GJ, Murphy ML, Schmidt EW, et al. Orbital myositis as a paraneoplastic syndrome. Arch Ophthalmol 1994;112:380–6.
188. Spraul CW, Lang GE, Lang GK. [Orbital myopathy in metastatic malignant paraganglioma: a paraneoplastic syndrome?]. Klin Monbl Augenheilkd 1996;209:153–7.